

JIALIANG WANG, PH.D.

T4224 Medical Center North, Nashville, TN 37232-2380

Tel: 615.936.6421; Fax: 615.343.8104; Email: jialiang.wang@vanderbilt.edu

<http://www.mc.vanderbilt.edu/root/vumc.php?site=neurosurgery&doc=30181>

ACADEMIC APPOINTMENT	Assistant Professor Department of Neurological Surgery (Primary) Department of Cancer Biology (Secondary) Department of Pharmacology (Secondary) Vanderbilt University Medical Center	08/2010- 09/2010- 10/2014-
	Adjunct Assistant Professor School of Graduate Studies and Research Meharry Medical College	08/2014-
EDUCATION	Ph.D. in Biochemistry University of North Carolina at Chapel Hill	2005
	M.S. in Biochemistry Institute of Microbiology, Chinese Academy of Sciences, Beijing, China	2000
	B.S. in Biology Zhejiang University, Hangzhou, China	1996
PROFESSIONAL TRAINING	Research Associate. Mentor: Dr. Bruce Sullenger Duke Translational Research Institute, Duke University	2009-2010
	Research Associate. Mentor: Dr. Jeremy Rich Brain Tumor Center, Duke University	2007-2008
	Postdoctoral Fellow. Mentor: Dr. Wendell Yarbrough Department of Cancer Biology, Vanderbilt University	2005-2007
AWARDS AND HONORS	Future Leaders in Translational Research American Association for Cancer Research	2010
	Basic Research Fellowship American Brain Tumor Association	2008
	Outstanding Student Scholarship Zhejiang University, Hangzhou, China	1995
	“Yao, Yi-Ming” Scholarship Zhejiang University, Hangzhou, China	1994
	Outstanding Student Scholarship Zhejiang University, Hangzhou, China	1993

SCHOLARLY SOCIETIES	American Association of Cancer Research	2006-
	Radiation Research Society	2010-
	Society of Neuro-Oncology	2011-
INVITED TALKS	Pediatric Grand Rounds, MD Anderson Cancer Center. <i>Notch-targeted Combination Therapy for Glioblastoma and Cancer Stem cells</i>	2012
	58 th Annual Meeting of the Radiation Research Society. <i>Targeting Radiation Resistance in Glioblastoma Stem Cells.</i>	2012
	Brain Tumor SPORE seminars, University of Alabama. <i>Combination Therapies for Treating Glioblastoma</i>	2014
	13 th Annual Meeting of Discovery on Target symposium. <i>Targeting BET bromodomain Proteins in Molecularly Heterogeneous Glioblastoma</i>	2014
	Joint Cancer Lecture Series, Emory University. <i>Brain Cancers: Inside and Out</i>	2016
SELECTED PUBLICATIONS	Peer Reviewed Articles: Loganathan SN, Tang N, Fleming JT, Ma Y, Guo Y, Borinstein SC, Chiang C, <u>Wang J</u> , BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing Sarcoma, Oncotarget, In Press	
	Ma Y, Tang N, Thompson RC, Mobley B, Clark SW, Sarkaria JN, <u>Wang J</u> . InsR/IGF1R pathway mediates resistance to EGFR inhibitors in glioblastoma. <i>Clinical Cancer Research</i> , 2016;22(7):1767-76. PMID: PMC4818693.	
	Gong Y, Ma Y, Sinyuk M, Loganathan S, Thompson RC, Sarkaria JN, , Chen W, Lathia JD, Mobley BC, Clark SW, <u>Wang J</u> . Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation. <i>Neuro Oncol.</i> 2016;18(1):48-57. PMID: 4677408.	
	Ma Y, Gong Y, Cheng Z, Loganathan S, Kao C, Sarkaria JN, Abel TW, <u>Wang J</u> . Critical functions of RhoB in support of glioblastoma tumorigenesis. <i>Neuro Oncol.</i> 2015;17(4):516-25. PMID: 4483068.	
	Song W, Ma Y, <u>Wang J</u> , Brantley-Sieders D, Chen J. JNK Signaling Mediates EPHA2-Dependent Tumor Cell	

Proliferation, Motility, and Cancer Stem Cell-like Properties in Non-Small Cell Lung Cancer. *Cancer Res.* 2014;74(9):2444-54. PMID: 4008716.

Wang H, Han M, Whetsell W Jr, Wang J, Rich J, Hallahan D, Han Z. Tax-interacting protein 1 coordinates the spatiotemporal activation of Rho GTPases and regulates the infiltrative growth of human glioblastoma. *Oncogene.* 2014;20;33(12):1558-69. PMID: 3965267

Wang J, Ma Y, Cooper MK. Cancer stem cells in glioma: challenges and opportunities. *Transl Cancer Res.* 2013;2(5):429-41. PMID: 3952560.
Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, Thompson RC, Muller S, Knapp S, Wang J. Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma. *Clin Cancer Res.* 2013;19(7):1748-59. PMID: 4172367

Shats I, Gatz ML, Chang JT, Mori S, Wang J, Rich J, Nevins JR. Using a stem cell-based signature to guide therapeutic selection in cancer. *Cancer Res.* 2011;71(5):1772-80. PMID: 3049992.

Wang J*, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, Rich JN, Sullenger BA. Notch promotes radioresistance of glioma stem cells. *Stem Cells.* 2010;28(1):17-28. PMID: 2825687. *:co-corresponding authors

Lathia JD, Gallagher J, Heddleston JM, Wang J, Eyler CE, Macsworlds J, Wu Q, Vasanthi A, McLendon RE, Hjelmeland AB, Rich JN. Integrin alpha 6 regulates glioblastoma stem cells. *Cell Stem Cell.* 2010;6(5):421-32. PMID: 2884275.

Wang H, Lathia JD, Wu Q, Wang J, Li Z, Heddleston JM, et al. Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. *Stem Cells.* 2009;27:2393-404. PMID: 2825688

Wang J, Wang H, Li Z, Wu Q, Lathia JD, McLendon RE, Hjelmeland AB, Rich JN. c-Myc is required for maintenance of glioma cancer stem cells. *PLoS One.* 2008;3(11):e3769. PMID: 2582454.

Wang J, An H, Mayo MW, Baldwin AS, Yarbrough WG. LZAP, a putative tumor suppressor, selectively inhibits NF-kappaB. *Cancer Cell.* 2007;12(3):239-51.

Wang J, He X, Luo Y, Yarbrough WG. A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2. *Biochem J.* 2006;393(Pt 2):489-501. PMID: 1360699.

Book Chapter:

Jialiang Wang, Jeremy Rich, Bruce Sullenger, "Notch Signaling and Cancer Stem Cells" in Notch Signaling in Embryology and Cancer, Landes Bioscience, ISBN: 978-1-4614-0898-7, August 15, 2011.

Patent:

Jialiang Wang, Compositions and Methods for Targeting Glioblastoma cells, US Patent: US 8,853,274 B1

**RESEARCH
SUPPORT**Active Research Support

R01 grant (1R01CA166492) Jialiang Wang (PI) 6/1/2013-
Agency: NIH/NCI 5/31/2018

Title: Targeting Radiation Resistance in Glioblastoma Stem Cells

The proposed studies will delineate Notch-mediated radiation resistant mechanisms in glioblastoma stem cells and use this knowledge to improve current radiotherapy for treating glioblastoma.

Completed Research Support

Research grant Jialiang Wang (PI) 7/1/2014-
Agency: Voice Against Brain Cancer Foundation 6/30/2015

Title: Personalized epigenetic therapy for treating glioblastoma

The goal of this proposal is to identify biomarkers that correlate with sensitivity to BET bromodomain inhibitors in glioblastoma.

Research Grant Jialiang Wang (PI) 1/1/2012-
Agency: Southeastern Brain Tumor Foundation 12/31/2012

Title: Novel Combination Treatment for Glioblastoma Stem Cells

The goal of this proposal is to develop Notch-targeted combination therapy for treating glioblastoma through a more effective killing of cancer stem cells.

Translational Grant Jialiang Wang (PI) 7/1/2011-
Agency: American Brain Tumor Association 6/30/2012

Title: Targeting the Notch Signaling Pathway in Molecularly Defined Tumor Subtypes of Glioblastoma

The application sought to explore sensitivity to Notch inhibition in different glioblastoma subtypes.